First New York Securities’s AstraZeneca AZN Stock Holding History

First New York Securities’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,500	Closed	-$107K	–	367
2014 Q3	$107K	Buy	+1,500	New	+$110K	0.08%	173
2014 Q2	–	Sell	-11,526	Closed	-$748K	–	203
2014 Q1	$748K	Buy	+11,526	New	+$744K	0.37%	68

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

First New York Securities's AZN Position: Q4 2014 in Review

First New York Securities sold out of AstraZeneca (AZN) in Q4 2014, closing a stake of 1,500 shares — an estimated $107K sold.

First New York Securities first reported a position in AZN in Q1 2014 and held it in 2 quarters. The position peaked at $748K in Q1 2014. 404 funds tracked by Wall St. Rank hold AZN as of Q4 2014.

First New York Securities reported no remaining AstraZeneca position as of Q4 2014 after selling out during the quarter.
First New York Securities sold 1,500 AstraZeneca shares in Q4 2014, an estimated $107K.
First New York Securities first reported a position in AstraZeneca in Q1 2014 and held it in 2 quarters.
First New York Securities's AstraZeneca position peaked at $748K in Q1 2014.
404 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2014.

Based on First New York Securities's 13F filing for Q4 2014, filed 9 Jan 2015.